New Medicines and Clinical Trials for Multiple Sclerosis: First Check Your Disease Course, the Evidence, and the Treatment’s Status
When you see news about a new medicine or “cell therapy” for multiple sclerosis (MS), first ask your usual neurologist to confirm your disease course and treatment goals. Then check the specific product’s approval or research status where you plan to receive care. If you are preparing to travel to China for a consultation, ask the research center whether prescreening is worthwhile for you and confirm the full visit schedule and costs. A registration number or a hospital’s involvement in research does not mean you qualify to enroll.
Key Points
- Fewer relapses, fewer new MRI lesions, slower worsening of function, and recovery of lost function are different goals. Results for groups of study participants cannot directly predict your individual outcome.
- Do not stop medication on your own to meet screening requirements. Ask your usual treating doctor and the research team to review your last dose date, the risks of switching treatment, and any required interval together.
- Contact your local healthcare team promptly if symptoms develop or worsen gradually. If you suddenly develop vision loss or blurred vision, weakness or numbness on one side, trouble with balance, difficulty speaking, changes in consciousness, or difficulty breathing, contact local emergency services immediately. Seek immediate assessment even if symptoms improve quickly. Do not decide for yourself whether this is an MS relapse or another condition, and do not wait for a response from an overseas research team.[11]
First Clarify What You Hope to Improve
Ask your doctor to explain whether you currently have relapsing, primary progressive, or secondary progressive MS, and whether you have had recent relapses or activity on imaging. Some people mainly experience attacks; others have no relapses for years but still gradually lose function. Different studies of the same medicine may involve different groups of patients.
Write down your main goals, such as reducing relapses or slowing the worsening of walking or hand function. Then ask the research team: How is the primary outcome measured, how long must a change persist to be confirmed, and what is it compared with? Hand test results do not directly mean recovery of all everyday functions, and changes in biomarkers do not directly prove that patients feel better or can manage daily life more easily.
How to Read New Medicine Results and Approval Information
Tolebrutinib: In 2026, the European Union approved Cenrifki for adults with secondary progressive MS who had had no relapses in the previous two years. “No relapses” does not necessarily mean no MRI activity, and this indication does not cover everyone with progressive MS. The HERCULES study compared the medicine with placebo in this specific group and found a lower risk of disability progression confirmed over at least six months in the treatment group. This does not mean that nerve damage has been repaired.[1–2]
This medicine carries a risk of serious liver injury, and the European prescribing information requires liver function monitoring before and during treatment. Being able to have blood tests on time, receive the results, and address abnormal findings is part of the treatment arrangements. The EU Cenrifki patient leaflet advises patients to tell their doctor immediately or seek medical advice if they develop possible symptoms of liver injury while taking the medicine, such as yellowing of the skin or whites of the eyes, dark urine, nausea, abdominal pain, or marked tiredness. If you cannot reach your treating team, seek local medical assessment immediately; contact local emergency services if symptoms are severe or worsen rapidly. If you miss a required liver function test, tell your doctor immediately and have the test as soon as possible.[1] The US FDA’s 2025 complete response letter raised concerns about serious liver injury and how to define the patient population with an appropriate balance of benefits and risks.[3] These regulatory documents come from different regions and different times. This guide has not confirmed the medicine’s current registration or availability in China. When consulting a local doctor and pharmacist, check the current approval, approved uses, and actual hospital supply.
Fenebrutinib: Company-reported results from the FENhance studies in relapsing MS showed a lower annualized relapse rate in the study medicine groups than with teriflunomide. The company also disclosed an imbalance in the number of reported deaths between the groups. These numbers alone cannot establish whether the deaths were related to the medicine, but the safety signal must not be ignored.[4] FENtrepid studied primary progressive MS and compared fenebrutinib with ocrelizumab. The company reported that the study met its predefined noninferiority goal; this does not prove that the new medicine is better.[5] These are study results released by the company. They do not establish that the medicine is approved in China or that a particular center has places available. Ask the research team to explain the study duration, comparison group, known safety information—including liver function abnormalities and infections—and how safety is monitored.
Ocrelizumab: Publicly available Chinese prescribing information lists indications for adults with relapsing MS and primary progressive MS. However, use still requires a doctor’s assessment and confirmation of the current prescribing information and hospital supply.[6] The ORATORIO-HAND study compared disability progression in people with primary progressive MS receiving ocrelizumab or placebo, including some older patients and patients with greater disability. Participants were aged 18–65 and met the study’s disability criteria. The combined outcome included worsening on a hand function test or disability score confirmed over 12 weeks. The published abstract reported that fewer participants in the study medicine group reached this combined outcome than in the placebo group (33% versus 40%).[7] This does not mean recovery of hand function and cannot guarantee individual benefit. Before treatment, discuss infection risks, infusion reactions, and testing and follow-up arrangements with your doctor.[6]
What Exactly Does Cell Therapy Mean?
Ask the provider to put in writing the cell type, product name, target, administration process, and whether it is routine medical care or part of a specific study. Do not treat all cell infusions as the same therapy.
A 2024 report described two patients with progressive MS who received CD19-targeted CAR-T therapy, with observations of safety and immune changes. Neither patient developed the neurotoxicity syndrome described in the report. However, the sample size and observation period were insufficient to rule out risks or prove long-term disease control or reversal of disability.[8] A CAR-T risk assessment should cover cytokine release syndrome, neurotoxicity, infections, emergency care capabilities, and long-term follow-up. The specific risks depend on the product and treatment protocol.
Autologous hematopoietic stem cell transplantation (AHSCT) is a separate approach involving stem cell collection, conditioning treatment, blood cell recovery, and long-term monitoring. The BEAT-MS registry describes a randomized study comparing transplantation with available drug treatment in a specific group of patients with treatment-resistant relapsing MS. Listed criteria include age 18–55 and at least two episodes of disease activity meeting the study’s definitions within the previous 36 months; primary progressive MS is excluded. These are only some of this study’s criteria, not universal requirements for other studies.[9] A registry entry and its planned completion date do not prove that transplantation is better than all medicines or that places in the study are available in China. Ask neuroimmunology and transplant teams to jointly assess your previous treatments, disease activity, infections, and organ health. Ask about conditioning treatment, serious infections, possible effects on fertility, recovery in hospital, and long-term follow-up after returning home.
How to Verify Research and Screening in China
- Ask the person providing the information for the study’s full name, registration number, sponsor, participating hospital, and specific research team. Check when the registry record was last updated, the study type, treatment groups, and inclusion and exclusion criteria. Then contact the center to confirm whether the relevant cohort is currently open. A global recruitment status or the existence of a registry entry does not mean that the hospital currently has places available.
- Prepare records of your diagnosis and disease course, relapse dates, all previous MRI reports and original images, changes in function, previous medicines and last dose dates, reasons for stopping treatment, and important infection and liver function records. Ask the center which file formats it accepts and what translation is required.
- Ask your usual treating doctor and the research team to discuss medication switching, any possible washout interval, and care while you wait. Any medication stoppage or change must be arranged by the responsible doctor. Passing prescreening means only that you can proceed to further assessments. Formal enrollment depends on screening results required by the protocol and the research team’s judgment.
- Before signing the consent form, ask about random assignment and the comparison group, possible benefits and risks, alternative treatments, testing frequency, what happens if you feel unwell or have a relapse, and who will take over treatment if you withdraw. In studies covered by China’s Measures for Ethical Review of Life Science and Medical Research Involving Humans, participants may withdraw at any time without giving a reason and should not be treated unfairly because of that decision.[12] Discuss the right to withdraw separately from arrangements for safe care: ask the team to explain the consequences of withdrawal, and discuss necessary safety follow-up, other treatment, and handover with your usual doctor. Ask the team to explain everything in language you can understand and allow time for questions.
Confirm Costs and Follow-up Care Before Traveling
Article 8 of China’s current Regulations for the Implementation of the Drug Administration Law states that drug clinical trial sponsors and institutions must not charge participants fees related to the clinical trial.[10] Ask the center to provide a written breakdown of who pays for failed screening, study tests, treatment of ordinary illnesses, travel and accommodation, interpreting and translation, care for trial-related harm, and costs after withdrawal. If it is unclear whether an item is trial-related, ask the research institution and ethics committee to explain. Rules for other types of research must be checked separately according to the nature of the study; drug trial rules should not be applied directly to all services.
Obtain a visit calendar and confirm where you must attend in person, which tests are required, and how long you are expected to stay for each visit. Do not assume visits can be completed remotely. Before arranging travel, agree with the research team and your doctor where you live on who will pass on results, whom to contact about abnormal findings, and how medication and follow-up testing will continue after you return home. A preliminary review or one outpatient visit does not mean you have been accepted for treatment.
Frequently Asked Questions
I meet several conditions listed on the website. Can I book flights now?
First contact the specific research center to confirm which cohorts are open and what documents are needed for prescreening. Ask about the possibility of failing on-site screening, costs, and arrangements for changing travel bookings. A website cannot replace formal screening.
I have not had a relapse for a long time. Can I join a study for relapsing MS?
Not necessarily. The study may require recent attacks or activity on imaging, and criteria vary by protocol. Ask your doctor to review your disease course and supporting evidence, then let the research team assess eligibility.
The study requires stopping medication. Can I stop early on my own?
Do not stop medication on your own. Ask your usual treating doctor and the research team to confirm your last dose, the required interval, and the risks and plans for managing them while you wait.
Does random assignment guarantee that I will receive the new medicine?
No. The comparison group may receive an existing medicine, placebo, or another option specified in the protocol. Before signing, ask for an explanation of what each group receives, how assignment works, what happens if your condition worsens, and treatment after withdrawal.
If two patients in a cell therapy study did not develop a certain toxicity, does that mean it is safe?
You cannot draw that conclusion. Small samples may miss rare risks or those that appear later. Ask the team to explain the product’s known risks, monitoring and emergency care capabilities, and the length of follow-up.
If a medicine is approved in the EU, can I get it at a hospital in China?
You cannot assume so. Check its current registration and approved uses in China, hospital pharmacy supply, your own eligibility, and monitoring arrangements. Approval abroad is a regulatory decision in another region.
What happens after the study ends or if I withdraw early?
In studies covered by the Chinese ethical review measures mentioned above, participants may withdraw at any time without giving a reason and should not be treated unfairly because of that decision.[12] Separately discuss necessary safety follow-up, further treatment, and handover with the research team and your usual treating doctor. Ask who will provide medical records and test results, how you will obtain medication, and who will cover the related costs.
Sources
Checked on: 2026-11-06. Study and approval status may change; verify them again when seeking advice.